Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effect of microRNA-543 (miR-543) on the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer (TNBC) cells, and the associated mechanism.

Methods

Human breast cancer cells (MDA-MB-231, HCC1937, and MCF-7, ZR-75–1) and normal human breast epithelial cell line (MCF10A) were transfected with miR-543 mimics or inhibitor using lipofectamine 2000. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting were used to determine the mRNA and protein expression levels of miR-543, actin-like protein 6A (ACTL6A), vimentin, Snail, and E-cadherin in breast cancer cells/tissue. Cell counting kit-8 (CCK-8), wound-healing, and Transwell assays were used to measure the effect of miR-543 on TNBC cell proliferation, invasion, and migration. Overall survival was determined using data from Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases. Bioinformatics analysis and luciferase reporter gene assay were used to determine the regulatory effect of miR-543 on ACTL6A.

Results

The level of expression of miR-543 was significantly lower in breast cancer cells/tissue than in normal human breast epithelial cell/tissue (p < 0.05). MicroRNA-543 expression level was significantly reduced in TNBC cells/tissue, relative to the other breast cancer cells/normal breast tissue (p < 0.05). MicroRNA-543 significantly suppressed tumor growth and the proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) of TNBC cells, in mouse xenograft model (p < 0.05).

Conclusions

miR-543 influences the biological behavior of TNBC cells by directly targeting ACTL6A gene. miR-543 could serve as a novel diagnostic and therapeutic target for TNBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62:220–41.

    Article  Google Scholar 

  2. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9:293–302.

    Article  CAS  Google Scholar 

  3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  CAS  Google Scholar 

  4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

    Article  CAS  Google Scholar 

  5. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8:1483–507.

    Article  Google Scholar 

  6. Lee KL, Kuo YC, Ho YS, Huang YH. 2019 Triple-negative breast cancer: current understanding and future therapeutic breakthrough targeting cancer stemness. Cancers. 11(9):1334.

  7. Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38:195.

    Article  Google Scholar 

  8. da Silva JL, Cardoso-Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020;145:102855. https://doi.org/10.1016/j.critrevonc.2019.102855.

    Article  PubMed  Google Scholar 

  9. Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res Treat. 2017;165:743–50.

    Article  Google Scholar 

  10. Valinezhad-Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. 2014 Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics. https://doi.org/10.1155/2014/970607

  11. Garofalo M, Croce CM. MicroRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011;51:25–43.

    Article  CAS  Google Scholar 

  12. Le XF, Merchant O, Bast RC, Calin GA. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron. 2010;3:137–47.

    Article  CAS  Google Scholar 

  13. Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17:152–63.

    Article  CAS  Google Scholar 

  14. Chen P, Xu W, Luo Y, Zhang Y, He Y. MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. Onco Targets Ther. 2017;10:1423–31.

    Article  CAS  Google Scholar 

  15. Li J, Dong G, Wang B, Gao W, Yang Q. MiR-543 promotes gastric cancer cell proliferation by targeting SIRT1. Biochem Biophys Res Commun. 2016;469:15–21.

    Article  CAS  Google Scholar 

  16. Yu L, Zhou L, Cheng Y, Sun L, Fan J. MicroRNA-543 acts as an oncogene by targeting PAQR3 in hepatocellular carcinoma. Am J Cancer Res. 2014;4:897–906.

    PubMed  PubMed Central  Google Scholar 

  17. Zhai F, Cao C, Zhang L, Zhang J. MiR-543 promotes colorectal cancer proliferation and metastasis by targeting KLF4. Oncotarget. 2017;8:59246–56.

    Article  Google Scholar 

  18. Haga CL, Phinney DG. MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem. 2012;287:42695–707.

    Article  CAS  Google Scholar 

  19. Bing L, Hong C, Li-Xin S, Wei G. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014;290:533–41.

    Article  Google Scholar 

  20. Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Quintanar-Jurado V, Maffuz-Aziz A. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS ONE. 2012;7:e31904.

    Article  CAS  Google Scholar 

  21. Krasteva V, Buscarlet M, Diaz-Tellez A, Bernard MA, Crabtree GR. The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function. Blood. 2012;120:4720–32.

    Article  CAS  Google Scholar 

  22. Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron. 2007;55:201–15.

    Article  CAS  Google Scholar 

  23. Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H. ACTL6A is co-amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 2017;31:35–49.

    Article  CAS  Google Scholar 

  24. Meng L, Wang X, Liao W, Liu J, Liao Y. BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. Oncol Rep. 2017;38:3327–34.

    Article  CAS  Google Scholar 

  25. Taulli R, Foglizzo V, Morena D, Coda DM, Ala U. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Oncogene. 2014;33:2354–62.

    Article  CAS  Google Scholar 

  26. Chen H, Pan H, Qian Y, Zhou W, Liu X. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 2018;17:4.

    Article  Google Scholar 

  27. Piletic K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016;90:2405–19.

    Article  CAS  Google Scholar 

  28. Yu Q, Zhang Z, He B, Wang H, Shi P. MiR-543 functions as tumor suppressor in ovarian cancer by targeting TWIST1. J Biol Regul Homeost Agents. 2020;34:101–10.

    CAS  PubMed  Google Scholar 

  29. Xu L, Yu J, Wang Z, Zhu Q, Wang W. MiR-543 functions as a tumor suppressor in glioma in vitro and in vivo. Oncol Rep. 2017;38:725–34.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported with grants from Jiangsu Health Commission (No. Y20180808), Jiangsu Institute of Cancer Research Fund (No. ZM201814), and Jiangsu Youth Fund (No. BK20181091).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China

    Y. L. Wang, R. H. Liang, C. Y. Wang, R. P. Zhang & S. Y. Wu

  2. Department of Breast Surgery, Baotou Cancer Hospital, No. 18 Tuanjie Street, Qingshan District, Baotou, 014030, Inner Mongolia, China

    X. Han & G. L. Zhang

Authors
  1. Y. L. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. H. Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. P. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Y. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. L. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YW designed the study and drafted the manuscript. RL, CW, and RZ were responsible for the collection and analysis of the experimental data. SW, XH, and GZ revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to G. L. Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by Ethical Committee of Baotou Cancer Hospital and conducted in accordance with the ethical standards.

Informed consent

Subjects signed the informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y.L., Liang, R.H., Wang, C.Y. et al. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene . Clin Transl Oncol 24, 84–92 (2022). https://doi.org/10.1007/s12094-021-02672-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02672-z

Keywords

Search

Navigation